2 weeks Ago By ABMN Staff
StockNews.com started coverage on shares of Titan Pharmaceuticals ( NASDAQ:TTNP – Free Report ) in a research note released on Monday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance Titan Pharmaceuticals stock opened at $5.27 on Monday. Titan Pharmaceuticals has a 1 year low of $4.
24 and a 1 year high of $14.80. The firm has a 50 day moving average price of $5.
88 and a 200 day moving average price of $6.33. Titan Pharmaceuticals ( NASDAQ:TTNP – Get Free Report ) last announced its quarterly earnings results on Thursday, August 15th.
The specialty pharmaceutical company reported ($2.29) earnings per share for the quarter. About Titan Pharmaceuticals Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally.
It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. Further Reading Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
